Tools

Search

Explore

Videos Channels Figures

Atmrix

About

Tools

Search

Explore

Videos Channels Figures

Atmrix

About

EI

Elizabeth Iorns

10/03/18

@ Y Combinator

The future of biotech will likely involve products that patients are willing to pay for, focusing on conditions that significantly impact their quality of life.

Video

YC

A Conversation with Elizabeth Iorns - Advice for Biotech Founders

@ Y Combinator

A Conversation with Elizabeth Iorns - Advice for Biotech Founders

10/03/18

Related Takeaways

EI

Elizabeth Iorns

10/03/18

@ Y Combinator

Recent approvals of gene therapies and cell-based therapies have opened new avenues for biotech companies to create marketable products.

PB

Paul Buchheit

03/07/18

@ Y Combinator

When evaluating biotech companies, the demand for their product is often clear, but the challenge lies in their ability to deliver on that promise.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

The focus for biotech companies is on de-risking their technology by obtaining experimental data and developing a viable therapeutic intervention, which is crucial before entering clinical trials.

JL

Jonathan Lim

04/30/25

@ a16z

In the current environment, the focus should be on developing products that can demonstrate clear impact on patients, whether through safety or efficacy.

LF

Lex Fridman Cast

03/25/25

@ Lex Fridman

Technological advancements, particularly in biomedical science, offer hope for significant breakthroughs that could improve health and quality of life.

DN

Daniel Nadler

03/04/25

@ Sequoia Capital

Personalized medicine, which tailors treatment plans to individual patients based on their specific medical cases, is on the horizon and could significantly improve life expectancy.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

Biotech fundraising is increasingly resembling traditional paths seen in software, with many funds showing interest in innovative science companies.

MS

Michael Skok

03/25/23

@ Harvard Innovation Labs

Focusing on biopharma companies as a target market allows for a more tailored data solution that meets their specific needs.

EI

Elizabeth Iorns

10/03/18

@ Y Combinator

Biotech MVPs are challenging to define because commercial revenue typically only comes after product approval, which many biotechs never achieve.